PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
April 26, 2024 08:30 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 16, 2024 16:30 ET
|
PaxMedica, Inc.
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast
November 09, 2023 08:00 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IBN, a leading communications organization focused on linking public companies to the investment community, has unveiled the latest episode of The...
PaxMedica Announces 1-for-17 Reverse Stock Split
October 30, 2023 11:30 ET
|
PaxMedica, Inc.
TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug...
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
October 26, 2023 13:51 ET
|
PaxMedica, Inc.
TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General...
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)
October 18, 2023 10:10 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...